Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
06. November 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results
31. Oktober 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast
17. Oktober 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors
19. September 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
02. August 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
— Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company’s third study of its FcRn inhibitor; top-line data expected by end of 2021 — —...
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
01. August 2019 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)
30. Juli 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast
19. Juli 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation
19. Juni 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference
04. Juni 2019 07:30 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...